Want to see SE:SPRINT full AI Analyst Report?
Total Valuation
Sprint Bioscience AB has a market cap or net worth of kr311.27M. The enterprise value is kr343.57.
Market Capkr311.27M
Enterprise Valuekr343.57
Share Statistics
Sprint Bioscience AB has 105,515,540 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding105,515,540
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Sprint Bioscience AB’s return on equity (ROE) is 0.77 and return on invested capital (ROIC) is 81.67%.
Return on Equity (ROE)0.77
Return on Assets (ROA)0.67
Return on Invested Capital (ROIC)81.67%
Return on Capital Employed (ROCE)0.82
Revenue Per Employee5.57M
Profits Per Employee3.06M
Employee Count30
Asset Turnover1.22
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Sprint Bioscience AB is 4.1. Sprint Bioscience AB’s PEG ratio is -0.00309.
PE Ratio4.1
PS Ratio0.81
PB Ratio1.14
Price to Fair Value1.14
Price to FCF1.63
Price to Operating Cash Flow4.51
PEG Ratio-0.00309
Income Statement
In the last 12 months, Sprint Bioscience AB had revenue of 167.17M and earned 91.74M in profits. Earnings per share was 0.99.
Revenue167.17M
Gross Profit97.33M
Operating Income97.33M
Pretax Income91.74M
Net Income91.74M
EBITDA98.40M
Earnings Per Share (EPS)0.99
Cash Flow
In the last 12 months, operating cash flow was 68.95M and capital expenditures -504.00K, giving a free cash flow of 68.45M billion.
Operating Cash Flow68.95M
Free Cash Flow68.45M
Free Cash Flow per Share0.65
Dividends & Yields
Sprint Bioscience AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.49
52-Week Price Change426.79%
50-Day Moving Average3.35
200-Day Moving Average2.78
Relative Strength Index (RSI)40.86
Average Volume (3m)339.14K
Important Dates
Sprint Bioscience AB upcoming earnings date is Nov 11, 2026, TBA (Confirmed).
Last Earnings DateAug 26, 2026
Next Earnings DateNov 11, 2026
Ex-Dividend Date―
Financial Position
Sprint Bioscience AB as a current ratio of 7.60, with Debt / Equity ratio of 0.00%
Current Ratio7.60
Quick Ratio7.60
Debt to Market Cap0.00
Net Debt to EBITDA-1.29
Interest Coverage Ratio15.68
Taxes
In the past 12 months, Sprint Bioscience AB has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Sprint Bioscience AB EV to EBITDA ratio is 0.10, with an EV/FCF ratio of 0.11.
EV to Sales0.06
EV to EBITDA0.10
EV to Free Cash Flow0.11
EV to Operating Cash Flow0.11
Balance Sheet
Sprint Bioscience AB has kr93.26M in cash and marketable securities with kr0.00 in debt, giving a net cash position of kr93.26M billion.
Cash & Marketable Securitieskr93.26M
Total Debtkr0.00
Net Cashkr93.26M
Net Cash Per Sharekr0.88
Tangible Book Value Per Sharekr1.29
Margins
Gross margin is 78.03%, with operating margin of 58.22%, and net profit margin of 54.88%.
Gross Margin78.03%
Operating Margin58.22%
Pretax Margin54.88%
Net Profit Margin54.88%
EBITDA Margin58.86%
EBIT Margin58.22%
Analyst Forecast
The average price target for Sprint Bioscience AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast135.48%
EPS Growth Forecast―